Content area
Full Text
Struggling Idera Pharmaceutical Inc. (Nasdaq: IDRA) says it raised enough money in a recent public offering to make it through the fourth quarter. The Cambridge, Mass.-based developer of treatments for psoriasis and lupus reported in a May 15 filing with the U.S. Securities and Exchange Commission that a review of its 2012 financial statements caused accounting firm Ernst & Young LLP to raise "substantial doubt" about the company's ability to continue as a growing concern, or without the threat of liquidation.
Ernst & Young raised the doubt because of Idera's...